GRAIL (NASDAQ:GRAL) Insider Andrew John Partridge Sells 1,491 Shares

GRAIL, Inc. (NASDAQ:GRAL) insider Andrew John Partridge sold 1,491 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $61.08, for a total value of $91,070.28. Following the completion of the sale, the insider directly owned 163,738 shares of the company’s stock, valued at $10,001,117.04. The trade was a 0.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

GRAIL Price Performance

Shares of NASDAQ:GRAL traded down $6.57 during trading on Friday, hitting $59.98. The company had a trading volume of 760,283 shares, compared to its average volume of 809,610. The stock has a market cap of $2.57 billion, a price-to-earnings ratio of -5.78 and a beta of 3.15. GRAIL, Inc. has a one year low of $29.95 and a one year high of $118.84. The company has a fifty day simple moving average of $57.27 and a two-hundred day simple moving average of $75.49.

GRAIL (NASDAQ:GRAL) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($2.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.76) by $0.47. The business had revenue of $40.79 million during the quarter, compared to analyst estimates of $39.16 million. GRAIL had a negative return on equity of 16.42% and a negative net margin of 253.22%. On average, equities research analysts anticipate that GRAIL, Inc. will post -10.99 earnings per share for the current year.

Hedge Funds Weigh In On GRAIL

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE grew its position in shares of GRAIL by 29.0% during the 1st quarter. Bank of America Corp DE now owns 914,114 shares of the company’s stock worth $47,241,000 after buying an additional 205,611 shares in the last quarter. California State Teachers Retirement System grew its position in shares of GRAIL by 27.9% during the 1st quarter. California State Teachers Retirement System now owns 44,470 shares of the company’s stock worth $2,298,000 after buying an additional 9,696 shares in the last quarter. Empowered Funds LLC bought a new position in shares of GRAIL during the 1st quarter worth $311,000. Gamco Investors INC. ET AL grew its position in shares of GRAIL by 170.7% during the 1st quarter. Gamco Investors INC. ET AL now owns 66,758 shares of the company’s stock worth $3,450,000 after buying an additional 42,100 shares in the last quarter. Finally, Sei Investments Co. grew its position in shares of GRAIL by 53.0% during the 1st quarter. Sei Investments Co. now owns 12,092 shares of the company’s stock worth $625,000 after buying an additional 4,191 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on GRAL. Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a research note on Tuesday, April 21st. Canaccord Genuity Group decreased their price target on GRAIL from $105.00 to $80.00 and set a “buy” rating for the company in a research note on Friday, February 20th. Guggenheim decreased their price target on GRAIL from $130.00 to $75.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Morgan Stanley decreased their price target on GRAIL from $110.00 to $60.00 and set an “equal weight” rating for the company in a research note on Tuesday, February 24th. Finally, The Goldman Sachs Group began coverage on GRAIL in a research note on Friday. They set a “neutral” rating and a $60.00 price target for the company. Four research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, GRAIL currently has a consensus rating of “Hold” and an average target price of $67.00.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.